Andrew Mok

Q: What is Andrew Mok's success rate?

Andrew Mok currently has a success rate of 91.21070085965715.

Q: What is the average return of Andrew Mok's calls?

Their stock ratings have generated an average return of 5.771765051866231.

Barclays | Healthcare

Andrew Mok is an analyst from Barclays specializing in the Healthcare sector. Ranked #1856 out of 4678 analysts, they have issued 131 stock ratings with a success rate of 91.21% and an average return of 5.77%.

Andrew Mok has a well-established track record, with 131 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 91.21% and an average return of 5.77%, underscoring their expertise and ability to identify winning opportunities for investors.

#1856

Out of 4678

131

Total Ratings

+91.21%

Success Rate

+5.77%

Average Return

Recent Ratings Analysis

OSCR

Buy

Jun 10, 2026

Target

$35.00

Current

$27.85

Performance

0.00%

Andrew Mok rated OSCR as Overweight on Jun 10, 2026, setting a price target of 35. Shares have remained stable near 27.85, leaving the 35 target still in play.

AGL

Hold

May 26, 2026

Target

$81.00

Current

$101.70

Performance

19.27%

On May 26, 2026, AGL was given a Equal-Weight rating by Andrew Mok, with a target price of 81. The stock rallied from 101.7 to 101.7 after the Hold rating, surprising to the upside.

UNH

Buy

May 26, 2026

Target

$429.00

Current

$407.46

Performance

8.12%

UNH received a Overweight rating from Andrew Mok on May 26, 2026, aiming for 429. Momentum has favored the Buy call, with shares climbing from 407.46 to 407.46, rewarding those who trusted the recommendation.

PRVA

Hold

May 26, 2026

Target

$24.00

Current

$22.90

Performance

3.15%

On May 26, 2026, Andrew Mok published a Equal-Weight outlook on PRVA, with a target of 24. Sideways action left the Hold view intact, with no major move since 22.9.

MOH

Sell

May 26, 2026

Target

$199.00

Current

$197.89

Performance

12.31%

Andrew Mok on May 26, 2026 assigned MOH a Underweight rating, with a price target of 199. The market validated the bearish call with a pullback to 197.89.

HUM

Hold

May 26, 2026

Target

$344.00

Current

$364.38

Performance

20.78%

On May 26, 2026, Andrew Mok reaffirmed HUM with a Equal-Weight rating, targeting 344. Market strength beyond 364.38 went further than the conservative outlook suggested.

ASTH

Buy

May 26, 2026

Target

$50.00

Current

$38.73

Performance

0.49%

ASTH was rated Overweight by Andrew Mok on May 26, 2026, with a price objective of 50. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

CVS

Buy

May 26, 2026

Target

$106.00

Current

$98.02

Performance

8.03%

On May 26, 2026, Andrew Mok initiated coverage on CVS with a Overweight rating and target of 106. The stock’s climb of 8.03% since the call highlights the foresight in the rating.

CNC

Buy

May 26, 2026

Target

$75.00

Current

$65.34

Performance

14.21%

Andrew Mok issued a Overweight recommendation for CNC on May 26, 2026, price target set at 75. Investors following the Buy call captured upside momentum, with shares now at 65.34.

ALHC

Hold

May 26, 2026

Target

$16.00

Current

$20.56

Performance

28.26%

On May 26, 2026, ALHC was evaluated by Andrew Mok, who gave a Equal-Weight rating and target of 16. Investors who stayed in despite the Hold saw upside of 28.26%.

CI

Hold

May 26, 2026

Target

$304.00

Current

$295.81

Performance

5.33%

Andrew Mok rated CI as Equal-Weight on May 26, 2026, setting a price target of 304. Despite the Hold call, shares climbed 5.33% to 295.81, revealing unexpected momentum.

ELV

Buy

May 26, 2026

Target

$480.00

Current

$404.56

Performance

4.31%

On May 26, 2026, ELV was given a Overweight rating by Andrew Mok, with a target price of 480. The stock traded sideways with a 4.31% move, keeping the bullish thesis unresolved.

RDNT

Buy

May 20, 2026

Target

$65.00

Current

$58.16

Performance

7.29%

RDNT received a Overweight rating from Andrew Mok on May 20, 2026, aiming for 65. Momentum has favored the Buy call, with shares climbing from 58.16 to 58.16, rewarding those who trusted the recommendation.

LMRI

Buy

May 20, 2026

Target

$9.00

Current

$9.04

Performance

22.16%

On May 20, 2026, Andrew Mok published a Overweight outlook on LMRI, with a target of 9. Shares gained 22.16%, underscoring the accuracy of the bullish outlook toward 9.

AVAH

Buy

May 18, 2026

Target

$9.00

Current

$6.89

Performance

-10.52%

Andrew Mok on May 18, 2026 assigned AVAH a Overweight rating, with a price target of 9. The call has struggled to gain traction, with shares losing 10.52%.

ADUS

Sell

May 15, 2026

Target

$92.00

Current

$93.17

Performance

2.41%

On May 15, 2026, Andrew Mok reaffirmed ADUS with a Underweight rating, targeting 92. Price action has been neutral, giving no verdict on the Sell call.

DVA

Hold

May 08, 2026

Target

$194.00

Current

$198.54

Performance

-0.06%

DVA was rated Equal-Weight by Andrew Mok on May 08, 2026, with a price objective of 194. Flat performance suggests the Hold view was reasonable.

THC

Buy

May 05, 2026

Target

$238.00

Current

$164.77

Performance

-11.85%

On May 05, 2026, Andrew Mok initiated coverage on THC with a Overweight rating and target of 238. The Buy call has yet to be validated as shares remain 73.23 away from the target.

EHC

Buy

May 05, 2026

Target

$140.00

Current

$103.35

Performance

-1.72%

Andrew Mok issued a Overweight recommendation for EHC on May 05, 2026, price target set at 140. The target of 140 remains in play, though confirmation will depend on future moves.

ACHC

Hold

May 01, 2026

Target

$25.00

Current

$23.91

Performance

—

On May 01, 2026, ACHC was evaluated by Andrew Mok, who gave a Equal-Weight rating and target of 25. Hold sentiment was validated by subdued trading with no breakout beyond 23.91.

UHS

Buy

Apr 28, 2026

Target

$238.00

Current

$144.82

Performance

-10.90%

Andrew Mok rated UHS as Overweight on Apr 28, 2026, setting a price target of 238. The stock has underperformed, dropping 10.90% despite the bullish target of 238.

HCA

Buy

Apr 27, 2026

Target

$496.00

Current

$373.34

Performance

-16.25%

On Apr 27, 2026, HCA was given a Overweight rating by Andrew Mok, with a target price of 496. Despite the Buy call, shares fell from 373.34 to 373.34, challenging the optimistic stance.

CYH

Hold

Apr 23, 2026

Target

$3.00

Current

$2.97

Performance

19.28%

CYH received a Equal-Weight rating from Andrew Mok on Apr 23, 2026, aiming for 3. Investors saw gains of 19.28% that the cautious stance didn’t fully capture.

SGRY

Hold

Mar 03, 2026

Target

$18.00

Current

$14.20

Performance

2.01%

On Mar 03, 2026, Andrew Mok published a Equal-Weight outlook on SGRY, with a target of 18. Sideways action left the Hold view intact, with no major move since 14.2.

BKD

Buy

Feb 03, 2026

Target

$18.00

Current

$13.10

Performance

-17.30%

Andrew Mok on Feb 03, 2026 assigned BKD a Overweight rating, with a price target of 18. The call has struggled to gain traction, with shares losing 17.30%.

Frequency Asked Questions

Who is Andrew Mok?

Andrew Mok is an analyst from Barclays specializing in the Healthcare sector.

What is Andrew Mok's success rate?

Andrew Mok currently has a success rate of +91.21%.

How many ratings has Andrew Mok issued?

Andrew Mok has issued 131 stock ratings so far.

What is the average return of Andrew Mok's calls?

Their stock ratings have generated an average return of +5.77%.

What is Andrew Mok's ranking?

Andrew Mok is ranked #1856 out of 4678 analysts.

What types of ratings does Andrew Mok give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andrew Mok?

You can follow Andrew Mok by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andrew Mok?

Their latest rating was a Buy on OSCR issued on 2026-06-10.